The Right Bug in the Right Place: Opportunities for Bacterial Vaginosis Treatment

Overview

Journal NPJ Biofilms Microbiomes

Date 2022 May 2

PMID 35501321

Authors

Shengru Wu

Luisa Warchavchik Hugerth

Ina Schuppe-Koistinen

Juan Du

Affiliations

Soon will be listed here.

Abstract

Bacterial vaginosis (BV) is a condition in which the vaginal microbiome presents an overgrowth of obligate and facultative anaerobes, which disturbs the vaginal microbiome balance. BV is a common and recurring vaginal infection among women of reproductive age and is associated with adverse health outcomes and a decreased quality of life. The current recommended first-line treatment for BV is antibiotics, despite the high recurrence rate. Live biopharmaceutical products/probiotics and vaginal microbiome transplantation (VMT) have also been tested in clinical trials for BV. In this review, we discuss the advantages and challenges of current BV treatments and interventions. Furthermore, we provide our understanding of why current clinical trials with probiotics have had mixed results, which is mainly due to not administering the correct bacteria to the correct body site. Here, we propose a great opportunity for large clinical trials with probiotic strains isolated from the vaginal tract (e.g., Lactobacillus crispatus) and administered directly into the vagina after pretreatment.

Citing Articles

An in silico framework for the rational design of vaginal probiotic therapy.

Lee C, Bonakdar S, Arnold K PLoS Comput Biol. 2025; 21(2):e1012064.

PMID: 39951429 PMC: 11867318. DOI: 10.1371/journal.pcbi.1012064.

Ecology meets reproductive medicine in HIV prevention: the case for geography-informed approaches for bacterial vaginosis in Africa.

Passmore J, Ngcapu S, Gitome S, Kullin B, Welp K, Martin D Front Reprod Health. 2024; 6:1431306.

PMID: 39665036 PMC: 11631894. DOI: 10.3389/frph.2024.1431306.

Exploring the Clinical Signatures of Cervical Dysplasia Patients and Their Association With Vaginal Microbiota.

Cheng L, Yan C, Yang Y, Hong F, Du J Cancer Med. 2024; 13(23):e70440.

PMID: 39641435 PMC: 11622153. DOI: 10.1002/cam4.70440.

Comparative efficacy of oral and vaginal probiotics in reducing the recurrence of bacterial vaginosis: a double-blind clinical trial.

Rezazadeh M, Zanganeh M, Jarahi L, Fatehi Z BMC Womens Health. 2024; 24(1):575.

PMID: 39462408 PMC: 11515199. DOI: 10.1186/s12905-024-03418-z.

Defining Vaginal Community Dynamics: daily microbiome transitions, the role of menstruation, bacteriophages, and bacterial genes.

Hugerth L, Krog M, Vomstein K, Du J, Bashir Z, Kaldhusdal V Microbiome. 2024; 12(1):153.

PMID: 39160615 PMC: 11331738. DOI: 10.1186/s40168-024-01870-5.

References

Dover S, Aroutcheva A, Faro S, Chikindas M . NATURAL ANTIMICROBIALS AND THEIR ROLE IN VAGINAL HEALTH: A SHORT REVIEW. Int J Probiotics Prebiotics. 2011; 3(4):219-230. PMC: 2908489. View

Czaja C, Stapleton A, Yarova-Yarovaya Y, Stamm W . Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol. 2008; 2007:35387. PMC: 2216064. DOI: 10.1155/2007/35387. View

Bradshaw C, Brotman R . Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis. 2015; 15:292. PMC: 4518586. DOI: 10.1186/s12879-015-1027-4. View

Mastromarino P, Macchia S, Meggiorini L, Trinchieri V, Mosca L, Perluigi M . Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 2008; 15(1):67-74. DOI: 10.1111/j.1469-0691.2008.02112.x. View

Bohbot J, Darai E, Bretelle F, Brami G, Daniel C, Cardot J . Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod. 2017; 47(2):81-86. DOI: 10.1016/j.jogoh.2017.11.005. View

Jacob L, John M, Kalder M, Kostev K . Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. Curr Med Mycol. 2018; 4(1):6-11. PMC: 6101156. DOI: 10.18502/cmm.4.1.27. View

Puebla-Barragan S, Reid G . Probiotics in Cosmetic and Personal Care Products: Trends and Challenges. Molecules. 2021; 26(5). PMC: 7956298. DOI: 10.3390/molecules26051249. View

Anukam K, Osazuwa E, Osemene G, Ehigiagbe F, Bruce A, Reid G . Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006; 8(12-13):2772-6. DOI: 10.1016/j.micinf.2006.08.008. View

Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R . Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003; 35(2):131-4. DOI: 10.1016/S0928-8244(02)00465-0. View

10.

Aldunate M, Srbinovski D, Hearps A, Latham C, Ramsland P, Gugasyan R . Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol. 2015; 6:164. PMC: 4451362. DOI: 10.3389/fphys.2015.00164. View

11.

Lev-Sagie A, Goldman-Wohl D, Cohen Y, Dori-Bachash M, Leshem A, Mor U . Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019; 25(10):1500-1504. DOI: 10.1038/s41591-019-0600-6. View

12.

Vodstrcil L, Walker S, Hocking J, Law M, Forcey D, Fehler G . Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis. 2014; 60(7):1042-53. DOI: 10.1093/cid/ciu1130. View

13.

Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H . A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents. 2006; 28 Suppl 1:S30-4. DOI: 10.1016/j.ijantimicag.2006.05.008. View

14.

Castro J, Machado D, Cerca N . Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors. ISME J. 2019; 13(5):1306-1317. PMC: 6474217. DOI: 10.1038/s41396-018-0337-0. View

15.

Kalia N, Singh J, Kaur M . Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19(1):5. PMC: 6986042. DOI: 10.1186/s12941-020-0347-4. View

16.

Bradshaw C, Morton A, Hocking J, Garland S, Morris M, Moss L . High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006; 193(11):1478-86. DOI: 10.1086/503780. View

17.

Gordillo Altamirano F, Barr J . Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev. 2019; 32(2). PMC: 6431132. DOI: 10.1128/CMR.00066-18. View

18.

Blaser M . Fecal Microbiota Transplantation for Dysbiosis - Predictable Risks. N Engl J Med. 2019; 381(21):2064-2066. DOI: 10.1056/NEJMe1913807. View

19.

Vujic G, Jajac Knez A, Despot Stefanovic V, Kuzmic Vrbanovic V . Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2013; 168(1):75-9. DOI: 10.1016/j.ejogrb.2012.12.031. View

20.

Antonio M, Meyn L, Murray P, Busse B, Hillier S . Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis. 2009; 199(10):1506-13. DOI: 10.1086/598686. View